Silencing Brain Circuit Could Prevent and Reverse Chronic Pain

Groundbreaking research identifies a key brain region responsible for transforming acute pain into chronic pain, opening the door to targeted therapies.

Jan. 28, 2026 at 1:31am

Got story updates? Submit your updates here. ›

Researchers at the University of Colorado Boulder have discovered that a specific brain region called the caudal granular insular cortex (CGIC) plays a crucial role in determining whether pain signals become temporary warnings or prolonged, debilitating experiences. By silencing this brain circuit in animal models, the team was able to both prevent the development of chronic pain and reverse existing chronic pain, offering a potential target for revolutionary new therapies to address this widespread and debilitating condition.

Why it matters

Chronic pain affects roughly 20% of the adult population globally, significantly impacting quality of life and costing economies billions annually. The current landscape of chronic pain management is largely dominated by opioids, which carry significant risks of addiction and side effects. This research opens the door to precisely targeted therapies that could bypass the drawbacks of traditional pain medication.

The details

The study, published in the Journal of Neuroscience, found that the CGIC acts as a 'decision-maker' that determines whether pain signals should be temporary warnings or prolonged, debilitating experiences. By silencing this pathway in animal models, the researchers were able to effectively prevent and even reverse chronic pain, including the condition of allodynia, where even gentle touch becomes excruciating.

  • The study was published on January 28, 2026.

The players

University of Colorado Boulder

The institution where the groundbreaking research on the CGIC and chronic pain was conducted.

Linda Watkins

The senior author of the study and a researcher at the University of Colorado Boulder.

Jayson Ball

The first author of the study, who is now working at Neuralink, a company pioneering brain-machine interface technologies.

Neuralink

A company developing brain-machine interface technologies that could potentially be used to regulate the activity of the CGIC and treat chronic pain.

Centers for Disease Control and Prevention

The organization that provided statistics on the prevalence of chronic pain in the adult population.

Got photos? Submit your photos here. ›

What they’re saying

“Our paper used a variety of state-of-the-art methods to define the specific brain circuit crucial for deciding for pain to become chronic and telling the spinal cord to carry out this instruction. If this crucial decision maker is silenced, chronic pain does not occur. If it is already ongoing, chronic pain melts away.”

— Linda Watkins, Senior Author of the Study

“Now that we have access to tools that allow you to manipulate the brain, not based just on a general region but on specific sub-populations of cells, the quest for new treatments is moving much faster.”

— Jayson Ball, First Author of the Study

What’s next

Several exciting avenues for future treatment are emerging, including targeted infusions to modulate the activity of the CGIC, brain-machine interfaces to directly interact with the CGIC, and personalized pain management strategies based on neuroimaging and genetic testing.

The takeaway

This research represents a significant leap forward in our understanding of chronic pain and offers hope for a future where targeted therapies can effectively prevent and reverse this debilitating condition, potentially reducing reliance on opioids and other traditional pain medications.